3-V Biosciences is a biopharmaceutical company dedicated to discovering and developing novel therapeutics that will transform the treatment of infectious diseases.

Our goal is to improve human health by treating viral infections with an innovative strategy that takes advantage of viruses’ dependence on the host’s cellular machinery and pathways for replication. This approach holds the promise of treating infectious diseases in novel ways:

High barrier to the development of resistance – viruses depend on a  high mutation rate to develop resistance to direct-acting antivirals.  3-V’s approach of targeting host factors significantly decreases the ability of viral mutation to create resistance.

Broad spectrum activity – different viruses requiring the same host proteins or pathways will likely succumb to the same drug.  A single agent that inhibits one of these critical pathways could target all circulating strains of a particular virus (e.g. influenza), including strains that are resistant to traditional antiviral agents.  The same drug could potentially be used to treat other diseases caused by  different viruses that depend on that host pathway.

The entire 3-V team is committed to realizing this vision, harnessing rigorous, innovative science coupled with best-practices honed through years of experience in drug discovery and development.